HIM
SAGE

Hillsdale Investment Management’s Sage Therapeutics SAGE Stock Holding History

Hillsdale Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,400
Closed -$358K – 607
2021
Q4 		$358K Hold
8,400
– – 0.02% 394
2021
Q3 		$372K Hold
8,400
– – 0.03% 405
2021
Q2 		$477K Buy
+8,400
New +$594K 0.04% 391

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Hillsdale Investment Management's SAGE Position: Q1 2022 in Review

Hillsdale Investment Management sold out of Sage Therapeutics (SAGE) in Q1 2022, closing a stake of 8,400 shares — an estimated $358K sold.

Hillsdale Investment Management first reported a position in SAGE in Q2 2021 and held it in 3 quarters. The position peaked at $477K in Q2 2021. 212 funds tracked by Wall St. Rank hold SAGE as of Q1 2022.

  • Hillsdale Investment Management reported no remaining Sage Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Hillsdale Investment Management sold 8,400 Sage Therapeutics shares in Q1 2022, an estimated $358K.
  • Hillsdale Investment Management first reported a position in Sage Therapeutics in Q2 2021 and held it in 3 quarters.
  • Hillsdale Investment Management's Sage Therapeutics position peaked at $477K in Q2 2021.
  • 212 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2022.

Based on Hillsdale Investment Management's 13F filing for Q1 2022, filed 28 Apr 2022.